[
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer",
    "summary": "We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE)’s shares jumped by 1.8% earlier this week after the firm announced that its bladder cancer drug Padcev helped improve bladder cancer survival rates when combined with Merck’s […]",
    "url": "https://finnhub.io/api/news?id=e648541a1fdef3b7c8f532dcc7dabef45ee06cc247753bd47fc43993154e930d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755282660,
      "headline": "Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer",
      "id": 136376321,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE)’s shares jumped by 1.8% earlier this week after the firm announced that its bladder cancer drug Padcev helped improve bladder cancer survival rates when combined with Merck’s […]",
      "url": "https://finnhub.io/api/news?id=e648541a1fdef3b7c8f532dcc7dabef45ee06cc247753bd47fc43993154e930d"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness",
    "summary": "We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)’s shares have lost 16% year-to-date as investors continue to be disappointed by the dropping revenue of its GARDASIL HPV drug in China. They […]",
    "url": "https://finnhub.io/api/news?id=858c632a9b7797ea6f19fc63e9aa2cb46fc2e8e4e0cf66cb420301388d48c74a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755282638,
      "headline": "Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness",
      "id": 136376322,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)’s shares have lost 16% year-to-date as investors continue to be disappointed by the dropping revenue of its GARDASIL HPV drug in China. They […]",
      "url": "https://finnhub.io/api/news?id=858c632a9b7797ea6f19fc63e9aa2cb46fc2e8e4e0cf66cb420301388d48c74a"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs",
    "summary": "AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.",
    "url": "https://finnhub.io/api/news?id=8c7ecaa4347c659d636f57fb74c8536477449124626665b52fa7ca9f7ad73eeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755266400,
      "headline": "AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs",
      "id": 136370262,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.",
      "url": "https://finnhub.io/api/news?id=8c7ecaa4347c659d636f57fb74c8536477449124626665b52fa7ca9f7ad73eeb"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500: Profit Margins Cannot Hold",
    "summary": "Discover how tariff policies and extreme valuations are impacting S&P 500 sectors. Click for my strategy and analysis of various sectors in the current environment.",
    "url": "https://finnhub.io/api/news?id=b6c049ae34e94860ded0c5cc034fc7400f2633e1748557e57266cf8824ab9f1f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755261481,
      "headline": "S&P 500: Profit Margins Cannot Hold",
      "id": 136370403,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2208085849/image_2208085849.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover how tariff policies and extreme valuations are impacting S&P 500 sectors. Click for my strategy and analysis of various sectors in the current environment.",
      "url": "https://finnhub.io/api/news?id=b6c049ae34e94860ded0c5cc034fc7400f2633e1748557e57266cf8824ab9f1f"
    }
  },
  {
    "ts": null,
    "headline": "Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial",
    "summary": "The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.",
    "url": "https://finnhub.io/api/news?id=fd014a9f6d755d6b46e4d2217832fb0a3807d96f8c3643341f15db4f7b00b5bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755256800,
      "headline": "Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial",
      "id": 136376453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.",
      "url": "https://finnhub.io/api/news?id=fd014a9f6d755d6b46e4d2217832fb0a3807d96f8c3643341f15db4f7b00b5bc"
    }
  },
  {
    "ts": null,
    "headline": "After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?",
    "summary": "Pfizer beat expectations last quarter and it raised its guidance.",
    "url": "https://finnhub.io/api/news?id=22f1af567608854d9850f5e078fc9d4cf87f60d2d3f7e71676d3dbefd1bee734",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755256500,
      "headline": "After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?",
      "id": 136368182,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer beat expectations last quarter and it raised its guidance.",
      "url": "https://finnhub.io/api/news?id=22f1af567608854d9850f5e078fc9d4cf87f60d2d3f7e71676d3dbefd1bee734"
    }
  },
  {
    "ts": null,
    "headline": "Merck KGaA ventures into new territory in the US",
    "summary": "How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.",
    "url": "https://finnhub.io/api/news?id=aa19266b858c0945a50522cbf629983a42da93f6faab5af6208edaef21b6cce7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755244800,
      "headline": "Merck KGaA ventures into new territory in the US",
      "id": 136368183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.",
      "url": "https://finnhub.io/api/news?id=aa19266b858c0945a50522cbf629983a42da93f6faab5af6208edaef21b6cce7"
    }
  }
]